- Home
- ELAB vs BGLC Comparison
ELAB vs BGLC Comparison
Compare ELAB & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- BGLC
- Stock Information
- Founded
- ELAB 2020
- BGLC 2017
- Country
- ELAB United States
- BGLC Malaysia
- Employees
- ELAB N/A
- BGLC N/A
- Industry
- ELAB
- BGLC Medical Specialities
- Sector
- ELAB
- BGLC Health Care
- Exchange
- ELAB Nasdaq
- BGLC Nasdaq
- Market Cap
- ELAB 6.6M
- BGLC 5.8M
- IPO Year
- ELAB 2023
- BGLC N/A
- Fundamental
- Price
- ELAB $2.17
- BGLC $3.10
- Analyst Decision
- ELAB
- BGLC
- Analyst Count
- ELAB 0
- BGLC 0
- Target Price
- ELAB N/A
- BGLC N/A
- AVG Volume (30 Days)
- ELAB 77.7K
- BGLC 158.2K
- Earning Date
- ELAB 05-14-2025
- BGLC 05-15-2025
- Dividend Yield
- ELAB N/A
- BGLC N/A
- EPS Growth
- ELAB N/A
- BGLC N/A
- EPS
- ELAB N/A
- BGLC N/A
- Revenue
- ELAB N/A
- BGLC $9,265,870.00
- Revenue This Year
- ELAB N/A
- BGLC N/A
- Revenue Next Year
- ELAB N/A
- BGLC N/A
- P/E Ratio
- ELAB N/A
- BGLC N/A
- Revenue Growth
- ELAB N/A
- BGLC N/A
- 52 Week Low
- ELAB $1.95
- BGLC $2.01
- 52 Week High
- ELAB $939.96
- BGLC $8.40
- Technical
- Relative Strength Index (RSI)
- ELAB 37.11
- BGLC 49.12
- Support Level
- ELAB $2.06
- BGLC $3.13
- Resistance Level
- ELAB $2.23
- BGLC $5.07
- Average True Range (ATR)
- ELAB 0.18
- BGLC 0.49
- MACD
- ELAB 0.05
- BGLC -0.01
- Stochastic Oscillator
- ELAB 29.92
- BGLC 19.61
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.